Valeant Pays $12M To Settle Wellbutrin Antitrust Claims

Law360, New York (February 15, 2013, 7:14 PM ET) -- Valeant Pharmaceuticals International Inc. will pay at least $11.75 million to settle a class action brought by health insurers and other indirect purchasers, accusing it of conspiring to stifle generic versions of antidepressant Wellbutrin XL and monopolize the market, according to documents filed Friday in Pennsylvania federal court.

Under the terms of the settlement, which is still subject to court approval, Valeant will pay either $11.75 million plus the lesser of either $500,000 or 50 percent of the cost of notifying class members, or 30 percent of...
To view the full article, register now.